Susquehanna International Group’s PharmaCyte Biotech PMCB Stock Holding History

Susquehanna International Group’s Portfolio PMCB Stock Details PMCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-27,606	Closed	-$30.4K	–	13566
2025 Q2	$30.4K	Buy	27,606 +9,200	+50%	+$10.3K	﹤0.01%	12249
2025 Q1	$23K	Sell	18,406 -16,075	-47%	-$26.1K	﹤0.01%	12076
2024 Q4	$53.4K	Sell	34,481 -747	-2%	-$1.29K	﹤0.01%	11646
2024 Q3	$67.3K	Sell	35,228 -19,606	-36%	-$36.5K	﹤0.01%	11254
2024 Q2	$107K	Buy	54,834 +13,646	+33%	+$29.4K	﹤0.01%	10981
2024 Q1	$97.6K	Buy	41,188 +19,160	+87%	+$41.5K	﹤0.01%	11232
2023 Q4	$47.6K	Buy	+22,028	New	+$47.7K	﹤0.01%	11733
2023 Q2	–	Sell	-106,886	Closed	-$311K	–	12889
2023 Q1	$311K	Buy	+106,886	New	+$314K	﹤0.01%	9646
2022 Q4	–	Sell	-16,624	Closed	-$47.6K	–	13392
2022 Q3	$40K	Sell	16,624 -61,985	-79%	-$157K	﹤0.01%	12334
2022 Q2	$178K	Buy	78,609 +50,547	+180%	+$110K	﹤0.01%	10810
2022 Q1	$65K	Buy	+28,062	New	+$62.3K	﹤0.01%	12173

Other funds holding PMCB

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EPM

Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Susquehanna International Group's PMCB Position: Q3 2025 in Review

Susquehanna International Group sold out of PharmaCyte Biotech (PMCB) in Q3 2025, closing a stake of 27,606 shares — an estimated $30.4K sold.

Susquehanna International Group first reported a position in PMCB in Q1 2022 and held it in 11 quarters. The position peaked at $311K in Q1 2023. 23 funds tracked by Wall St. Rank hold PMCB as of Q3 2025.

Susquehanna International Group reported no remaining PharmaCyte Biotech position as of Q3 2025 after selling out during the quarter.
Susquehanna International Group sold 27,606 PharmaCyte Biotech shares in Q3 2025, an estimated $30.4K.
Susquehanna International Group first reported a position in PharmaCyte Biotech in Q1 2022 and held it in 11 quarters.
Susquehanna International Group's PharmaCyte Biotech position peaked at $311K in Q1 2023.
23 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q3 2025.

Based on Susquehanna International Group's 13F filing for Q3 2025, filed 14 Nov 2025.